


# Stabilis



## Dactinomycin



Tradename

Cosmegen	Argentina, Australia, Austria, Canada, Finland, France, Greece, Iran, Italy, Malaysia, Mexico, New Zealand, Norway, Sweden, Switzerland, United States of America
Cosmegen Lyovac	Great Britain, Ireland, Romania
Dacilon	Chile, India, Peru
Dacmozen	India
Dactino	India
Dactinomicina	Chile, Colombia, Ecuador, Peru
Dactinomycin	New Zealand
Lyovac Cosmegen	Belgium, Germany, Luxembourg, Netherlands



### Stability in solutions

		10 µg/ml	20-25°C		10			4153
		10 µg/ml	20-25°C		10			4153
		9.8 µg/ml	25°C		24			1178
		10 µg/ml	20-25°C		10			4153
		10 µg/ml	20-25°C		10			4153
		9.8 µg/ml	25°C		24			1178





































### Factors which affect stability

				729
				857
				1322
Water for injection + bacteriostat				4153



## Compatibility

				
		Dactinomycin : 10 µg/ml Allopurinol sodium : 3 mg/ml		307
		Dactinomycin : 10 µg/ml Amifostine : 10 mg/ml		3
		Dactinomycin : 10 µg/ml Aztreonam : 40 mg/ml		99
		Dactinomycin : 10 µg/ml Etoposide phosphate : 5 mg/ml		1410
		Dactinomycin : 10 µg/ml Filgrastim : 30 µg/ml		244
		Dactinomycin : 10 µg/ml Fludarabine phosphate : 1 mg/ml		492
		Dactinomycin : 10 µg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Dactinomycin : 10 µg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Dactinomycin : 10 µg/ml Melphalan : 0.1 mg/ml		169
		Dactinomycin : 10 µg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Dactinomycin : 10 µg/ml Sargramostim : 10 µg/ml		335
		Dactinomycin : 10 µg/ml Teniposide : 0.1 mg/ml		905
		Dactinomycin : 10 µg/ml Thiotepa : 1 mg/ml		249
		Dactinomycin : 10 µg/ml Vinorelbine tartrate : 1 mg/ml		84
		Dactinomycin		4153



## Route of administration



## References








































	Type	Publication
3	Journal	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.

84	Journal	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Journal	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Journal	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Journal	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Journal	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	Journal	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Journal	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Journal	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
492	Journal	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
729	Journal	Rusmin S, Welton S, DeLuca P, DeLuca PP. Effect of inline filtration on the potency of drugs administered intravenously. Am J Hosp Pharm 1977 ; 34: 1071-1074.
857	Journal	Kanke M, Eubanks JL, DeLuca PP. Binding of selected drugs to a "treated" inline filter. Am J Hosp Pharm 1983 ; 40: 1323-1328.
905	Journal	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1178	Journal	Benvenuto JA, Anderson RW, Kerkof K, Smith RG, Loo TL. Stability and compatibility of antitumor agents in glass and plastic containers. Am J Hosp Pharm 1981 ; 38: 1914-1918.
1322	Journal	Ennis CE, Merritt RJ, Neff DN. In vitro study of inline filtration of medications commonly administered to pediatric cancer patients. JPEN 1983 ; 7: 156-158.
1410	Journal	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.

1423	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
4153	Manufacturer	Dactinomycin (Cosmegen Lyovac®) - Summary of Product Characteristics Orphan Europe (UF) Limited 2014



# Dictionary

 Anticancer drug	 injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Duration of stability
 Biosimilar	 conflicting data
 References	 Glass
 Water for Injection	 Not specified
 Hour	 NaCl 0,9% or Glucose 5%
 Glucose 5%	 Protect from light
 Polyvinyl chloride	 Factors which affect stability
 Filtration	 Induces
 Adsorption	 Reduced concentration
 Solvent	 Precipitation
 Compatibility	 Compound
 Compatible	 Sodium chloride 0,9%
 Immediate precipitation	 Incompatible
 Water for injection + antibacterial	 Route of administration
 Intravenous	 References
 Dictionary	